Support Our Work

Please donate so we can continue our work to reduce the stigma of psychiatric illness, encourage research, and support educational activities for behavioral health professionals and the public. Ways you can donate and help are on our Support and Donations page. Thank you!

More Info

Latest News Around the Web

Low Doses Of AD/HD Medication Appear Not To Affect Thyroid Or Growth Hormone Levels In Children Diagnosed With AD/HD, Small Study Indicates

Healio (5/25, Ellis) reports, “Among children diagnosed with” attention-deficit/hyperactivity disorder (AD/HD), “low doses of” AD/HD “medications did not affect thyroid or growth hormone levels,” researchers concluded in a study that included “118 children diagnosed with” AD/HD. The findings were published online March 9 in the Journal of Clinical Endocrinology & Metabolism.

Related Links:

— “Low-dose ADHD drugs do not affect thyroid function, growth hormone at 1 year “Brian Ellis, Healio, May 25, 2022

Telepsychiatry Appears To Have Maintained Standard Of Care For Patients With Schizophrenia Treated With LAIs, Researchers Say

MedPage Today (5/25, Monaco) reports, “The COVID-19 pandemic spurred” clinicians “to get creative in their shift to telepsychiatry for patients with schizophrenia, a subanalysis of the OASIS study” revealed. In fact, “across all types of visits – from routine to crisis visits – the percentage conducted via telepsychiatry increased more than threefold during the pandemic among 35 sites across the country,” researchers concluded.

Healio (5/25, Hemphill) reports, “According to the study, 94% of the investigators said telepsychiatry maintained the standard of care for patients with schizophrenia who are being treated with” long-acting injectables (LAIs). The findings were presented at the American Psychiatric Association 2022 Annual Meeting.

Related Links:

MedPage Today (requires login and subscription)

Rural US Counties Appear To Have Lower Odds Of Reaching Maximum Potential Buprenorphine Treatment Capacity, Data Indicate

Healio (5/24, Marabito) reports, “Rural counties in the United States had lower odds of reaching maximum potential buprenorphine treatment capacity,” researchers concluded after using “county-level Drug Enforcement Administration…data to determine the presence, absence and availability of buprenorphine treatment or opioid treatment programs” in US counties. The study also revealed that “counties with high populations of people with disabilities or without insurance also had lower odds of maximum treatment capacity with buprenorphine, a medication for opioid use disorder.” The findings were published online ahead of print in the July issue of the journal Drug and Alcohol Dependence.

Related Links:

— “Medication for opioid use disorder less accessible in rural counties “Maria Marabito, Healio, May 24, 2022

Small Scan Study Reveals White Matter Hyperintensities In Mixed Martial Arts Fighters

HealthDay (5/24, Thompson) reports, “The more that participants in mixed martial arts [MMA] spar in practice, the more likely they are to develop” white matter hyperintensities, that is, “brain structure changes that have been linked with brain injury,” investigators concluded. The magnetic resonance imaging study involving 92 professional MMA fighters also revealed that “more MMA sparring in practice is…associated with an increase in size of the caudate nucleus.” The findings were presented at the American Psychiatric Association 2022 Annual Meeting. Healio (5/24, Downey) also covers the study.

Related Links:

— “Mixed Martial Arts Fighters Show Signs of Brain Changes “Dennis Thompson, HealthDay, May 24, 2022

AHA urging DOJ to investigate routine denials from major health insurance companies

Healthcare Finance News (5/23, Lagasse) reports, “The American Hospital Association has sent a letter to the U.S. Department of Justice asking it to investigate routine denials from major health insurance companies.” Furthermore, “the AHA recommended that the DOJ establish a task force ‘to conduct False Claims Act investigations into commercial health insurance companies that are found to routinely deny patients access to services and deny payments to health care providers.’” This “recommendation was based in large part on a recent report released by the” HHS OIG, titled, “Some Medicare Advantage Organization Denials of Prior Authorization Requests Raise Concerns About Beneficiary Access to Medically Necessary Care.” The report “garnered reaction from” American Medical Association President Gerald E. Harmon, M.D., who said the report “uncovered information that mirrors physician experiences.” He added, “Surveys of physicians have consistently found that excessive authorization controls required by health insurers are persistently responsible for serious harm when necessary medical care is delayed, denied, or disrupted.”

Related Links:

— “AHA presses Department of Justice to investigate routine denials from health insurers “Jeff Lagasse, Healthcare Finance News, May 23, 2022

Foundation News

Nothing Found

It seems we can’t find what you’re looking for. Perhaps searching can help.